Quick Answer
Xenon Pharmaceuticals Inc. reported R&D Expense of $300.94 million for fiscal year 2025.
Xenon Pharmaceuticals Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $300.94M | +43.0% |
| 2024 | $210.39M | +25.6% |
| 2023 | $167.51M | +58.4% |
| 2022 | $105.77M | +40.2% |
| 2021 | $75.46M | +49.4% |
| 2020 | $50.52M | +30.1% |
| 2019 | $38.84M | +64.4% |
| 2018 | $23.63M | -7.6% |
| 2017 | $25.57M | +29.0% |
| 2016 | $19.83M | +30.9% |
| 2015 | $15.15M | +28.8% |
| 2014 | $11.77M | -4.3% |
| 2013 | $12.30M | +17.7% |
| 2012 | $10.46M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $77.05M | +35.3% | +2.8% |
| June 30, 2025 | $74.98M | +50.9% | +22.5% |
| March 31, 2025 | $61.20M | +38.3% | +7.4% |
| September 30, 2024 | $56.97M | +32.9% | +14.6% |
| June 30, 2024 | $49.70M | +12.9% | +12.3% |
| March 31, 2024 | $44.25M | +12.0% | +3.2% |
| September 30, 2023 | $42.88M | +45.7% | -2.6% |
| June 30, 2023 | $44.04M | +98.9% | +11.4% |
- Xenon Pharmaceuticals Inc. showed an increase of +43.0% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Xenon Pharmaceuticals Inc.’s r&d expense has grown by 2778.4% (from $10.46 million to $300.94 million).
- The most recent figure is from Xenon Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: